Compare Kotak Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Risk | Very High | Very High |
Rating | - | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 2.34 | 1.86 |
NAV | ₹12.74 | ₹38.00 |
Fund Started | 20 Nov 2023 | 25 Jun 2018 |
Fund Size | ₹467.92 Cr | ₹6455.55 Cr |
Exit Load | 0.5% for redemption within 30 Days | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
-
5.0
Min SIP Amount
₹100
₹100
Expense Ratio
2.34
1.86
NAV
₹12.74
₹38.00
Fund Started
20 Nov 2023
25 Jun 2018
Fund Size
₹467.92 Cr
₹6455.55 Cr
Exit Load
0.5% for redemption within 30 Days
Exit load of 1% if redeemed within 15 days.
1 Year | -4.68% | 0.24% |
3 Year | - | 25.85% |
5 Year | - | 16.74% |
1 Year
-4.68%
0.24%
3 Year
-
25.85%
5 Year
-
16.74%
Equity | 96.25% | 97.87% |
Cash | 3.75% | 2.13% |
Equity
96.25%
97.87%
Cash
3.75%
2.13%
Top 10 Holdings |
|
|
Top 10 Holdings
Sun Pharmaceutical Industries Ltd. | 12.86% |
Max Healthcare Institute Ltd. | 7.26% |
JB Chemicals & Pharmaceuticals Ltd. | 6.26% |
Divi's Laboratories Ltd. | 5.46% |
Cipla Ltd. | 4.84% |
Lupin Ltd. | 4.28% |
Apollo Hospitals Enterprise Ltd. | 3.99% |
Fortis Healthcare Ltd. | 3.78% |
Acutaas Chemicals Ltd. | 3.28% |
Jubilant Pharmova Ltd. | 3.21% |
Sun Pharmaceutical Industries Ltd. | 12.05% |
Cipla Ltd. | 7.90% |
Dr. Reddy's Laboratories Ltd. | 7.82% |
Divi's Laboratories Ltd. | 7.10% |
Mankind Pharma Ltd. | 6.44% |
Lupin Ltd. | 5.78% |
Aurobindo Pharma Ltd. | 5.19% |
Alkem Laboratories Ltd. | 3.66% |
Cohance Lifesciences Ltd. | 3.01% |
Syngene International Ltd. | 2.98% |
Name | - | - |
Start Date | - | - |
Name
-
-
Start Date
-
-
Description | The scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly Pharma, Healthcare, and allied sectors. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 20 Nov 2023 | 25 Jun 2018 |
Description
The scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly Pharma, Healthcare, and allied sectors.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
20 Nov 2023
25 Jun 2018